Chemotherapie des nicht-kleinzelligen Bronchialkarzinoms

  • H. O. Klein
Conference paper

Zusammenfassung

Ca. 78% der Bronchialkarzinome sind nicht-kleinzellige Bronchialkarzinome (Tabelle 1), wobei die Plattenepithelkarzinome überwiegen. Die Zahl der Adenokarzinome nimmt laufend zu (Monfardini et al. 1981; Valaitis et al. 1981). Im Gegensatz zum kleinzelligen Bronchialkarzinom konnte bei den nicht-kleinzelligen Bronchialkarzinomen in den letzten 15 Jahren kein wesentlicher Fortschritt bei der,Behandlung der inoperablen bzw. metastasierten Tumoren erzielt werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aisner J, Hansen HH (1981) Commentary: Current status of chemotherapy of non-small cell lung cancer. Cancer Treat Rep 65: 979–986PubMedGoogle Scholar
  2. Bitran JD, Desser RK, DeMeester TR, Golomb HM (1978a) Metastatic non-oat cell bronchogenic carcinoma. Therapy with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP). JAMA 240: 2743–2746CrossRefGoogle Scholar
  3. Bitran JD, Golomb HM, DeMeester TR et al. (1978b) Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62: 327–332Google Scholar
  4. Blum RH (1975) An overview of studies with adriamycin in the United States. Cancer Treat Rep (3) 6: 247–251Google Scholar
  5. Britell JY, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1978) Cis-dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichloro-diammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62: 1207–1210PubMedGoogle Scholar
  6. Brugarolas A, Hansen HH, Siegenthaler P (1980) Clinical study fo vincristine in adenocarcinoma of the lung. Eur J Cancer Clin Oncol 16: 1643–1644Google Scholar
  7. Cambarere JJ, Smith FP, Macdonald JS et al. (1981) CAMP (cyclophosphamide, doxorubicin, mehtotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung. Cancer Treat Rep 65: 317–310Google Scholar
  8. Casper ES, Gralla RJ, Kelsen DP, Natale RB, Sordillo P, Houghton A (1980a) Phase II evaluation of 4’-C 9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer. Cancer Treat Rep 64: 345–347Google Scholar
  9. Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW (1980b) Phase II evaluation of N-(Phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 64: 705–707Google Scholar
  10. Chahinian AP, Arnold DJ, Cohen JM et al. (1977) Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. JAMA 237: 2392–2396PubMedCrossRefGoogle Scholar
  11. Cohen M (1978) Bronchogenic carcinoma. In: Staquet MJ (ed) Randomized trials in cancer: A critical review by sites. Raven, New York, pp 297–329Google Scholar
  12. Cohen MH, Perevodchikova NJ (1979) Single agent chemotherapy of lung cancer. In: Muggia F, Rozencweig M (eds) Lung cancer: Progress in therapeutic research. Raven, New York, pp 343–374Google Scholar
  13. Cornell CJ, Hoth D, Pajak TF (1981) Phase II study of chlorozotocin in non-small cell carcinoma of the lung. Cancer Treat Rep 65: 734–735PubMedGoogle Scholar
  14. Creagan ET, Eagen RT, Fleming TR, Trytak S, Ingle JN, Kvols LK, Nichols WC (1980) Phase II evaluation of trizinate in patients with metastatic lung cancer. Cancer Treat Rep 64: 1057–1059PubMedGoogle Scholar
  15. Creagan ET, Eagan RT, Fleming TR, Frytak S, Nichols WC, Ingle JN, Kvols LK (1981) Phase II evaluation of PALA in patients with metastatic lung cancer. Cancer Treat Rep 65: 356–357PubMedGoogle Scholar
  16. Creech RH, Mehta CR, Cohen M et al. (1981) Results of a phase II protocol for evaluation of new chemotherapeutic regimes in patients with inoperable non-small cell lung carcinoma (EST-2575, Generation I). Cancer Treat Rep 65: 431–438PubMedGoogle Scholar
  17. Davies S, Rambotti P, Park YK (1981) Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 65: 955–958Google Scholar
  18. DeJager R, Longeval E, Klastersky J (1980) High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: A phase II clinical trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64: 1241–1346Google Scholar
  19. Denes AE, Presant CA, Bartolucci A (1982) Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): A pilot study of the southeastern cancer study group. Cancer Treat Rep 66: 199–200PubMedGoogle Scholar
  20. Drapkin R, Bjornsson S, Nacher C et al. (1980) Doxorubicin, cisplatin, and corynebacterium parvum in non-small cell bronchogenic carcinoma. Cancer Treat Rep 64: 1367–1369PubMedGoogle Scholar
  21. Durant KR, Berry RJ, Ellis F, Ridehalgh FR, Black JM, Hamilton WS (1971) Compari- son of treatment policies in inoperable bronchial carcinoma. Lancet 10: 715–719CrossRefGoogle Scholar
  22. Eagan RT, Ingle JN, Frytak S et al. (1977) Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 61: 1339–1345PubMedGoogle Scholar
  23. Eagan RT, Frytak S, Creagan ET, Ingle JN, Kvols LK, Coles DT (1979a) Phase II study of cyclophosphamide, adriamycin, and dis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 63: 1589–1591Google Scholar
  24. Eagan RT, Creagan ET, Ingle JN, Rubin J, Frytak S, Kvols LK, Fleming TR (1979b) VP-16, cyclophosphamide, adriamycin and cis-platinum (V: CAP I) in patients with metastatic adenocarcinoma of the lung. Tumori 65: 105–109Google Scholar
  25. Eagan RT, Fleming TR, Frytak S, Creagan ET, Ingle JN, Kvols LK (1980) A role of cisdichlorodiammineplatinum (II) in squamous cell lung cancer. Cancer Treat Rep 64: 87–91PubMedGoogle Scholar
  26. Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK (1981a) Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer. Cancer Treat Rep 65: 517–519Google Scholar
  27. Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK, Coles DT (1981b) Evaluation of VP-16–213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in andvanced large cell lung cancer. Cancer Treat Rep 65: 715–717Google Scholar
  28. Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK (1981c) Cyclophosphamide and VP 16–213 with or without cisplatin in squamous cell and small cell lung cancers. Cancer Treat Rep 65: 453–458Google Scholar
  29. Evans WK, Feld R, DeBoor G et al. (1980) Cyclophosphamide, adriamycin, and cis-platinum in the treatment of non-small cell lung cancer. Proc Am Assoc Cancer Res 21: 447Google Scholar
  30. Evans WK, Feld R, DeBoer G et al. (1981) Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma. Cancer Treat Rep 65: 947–954PubMedGoogle Scholar
  31. Fischer M, Mitrou PS (1980) Ergebnisse der Chemotherapie der inoperablen nicht-kleinzelligen Bronchialcarcinome. Internist (Berlin) 21: 95–107Google Scholar
  32. Furnas B, Williams SD, Cobleigh MA, Einhorn LH (1981) Vindesine an effective phase II agent in the treatment of non-small cell lung cancer. In: Brade W, Nagel GA, Seeber S (eds) Proceedings of the International Cinca Alkaloid Symposium-Vincesine, Frankfurt/Main, November 1980. Karger, Basel München Paris London New York Sydney, pp 342–343Google Scholar
  33. Gralla RJ, Raphael BG, Golbey RB, Young CW (1979) Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 63: 1343–1346PubMedGoogle Scholar
  34. Gralla RJ, Casper ES, Kelsen DP et al. (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95: 414–420PubMedGoogle Scholar
  35. Haas CD, Baker L, Thigpen T (1981) Phase II evaluation of dianhydrogalactitol in lung cancer: a southwest oncology group study. Cancer Treat Rep 65: 115–117PubMedGoogle Scholar
  36. Hansen HH, Rerth M (1979) Lung cancer. In: Pinedo HM (ed) Cancer chemotherapy 1979. The EORTC Cancer Chemotherapy Annual I. Excerpta Medica, Amsterdam Oxford, pp 267–291Google Scholar
  37. Hansen HH, Rerth M (1980) Lung cancer. In: Pinedo HM (ed) Cancer chemotherapy 1980. The EORTC Cancer Chemotherapy Annual II. Excerpta Medica, Amsterdam Oxford, pp 267–283Google Scholar
  38. Hong WK, Penacchio J, Pujatsch R et al. (1981) Vindesine versus vindesine with cis-platinum in metastatic non-small cell lung cancer. In: Brade W, Nagel GA, Seeber S (eds) Proceedings of the International Vinca Alkaloid Symposium Vindesine. Frankfurt/Main, 1980. Karger, Basel München Paris London New York Sydney, pp 398–404Google Scholar
  39. Houtte P van, Bondue H, Rocmans P et al. (1980) Adjuvant Immunotherapy by levami-sole in resectable lung cancer: a control study. Eur J Cancer Clin Oncol 16: 1596–1601Google Scholar
  40. Issel BF, Valdivieso M, Bodey GP (1978) Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with ftorafur, adriamycin, and cis-dichlorodiammineplatinum (II). Cancer Treat Rep 62: 1089–1091Google Scholar
  41. Jordan WM, Valdivieso M, Frankmann C, Gillespie M, Issell BF, Bodey GP, Freireich E (1981) Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive i. v. hyperalimentation. Cancer Treat Rep 65: 197–205PubMedGoogle Scholar
  42. Kelsen D, Gralla R, Stoopler M, Casper E, Cheng E, Kosloff C, Golbey R (1982) Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treat Rep 66: 247–251PubMedGoogle Scholar
  43. Klein HO, Christian E, Coerper C, Dias Wickramanayake P (1982) High-dose Ifosfamide and Mesna as continuous Infusion over Five Days-A Phase I/II Trial. 13th International Cancer Congress, Seattle, USA (Abstr Vol )Google Scholar
  44. Knost JA, Greco FA, Hande KR, Richardson RL, Fer MF, Oldham RK (1981) Cyclophosphamide, doxorubicin, and cis-platin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 65: 941–945PubMedGoogle Scholar
  45. Lad TE, Nelson RB, Diekamp U et al. (1981) Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: A randomized trial. Cancer Treat Rep 65: 973–978PubMedGoogle Scholar
  46. Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML (1977) Survival with inoperable lung cancer. Cancer 39: 303PubMedCrossRefGoogle Scholar
  47. Livingston R (1981) Combined modality therapy in lung cancer-1980. 3rd International Conference on the adjuvant Therapy of Cancer. March 18–21, 1981, Tucson, Arizona/USA (Abstr Vol 33 )Google Scholar
  48. Livingston RB, Mira J, O’Bryan RM (1981) Four-drug combination chemotherapy in extensive non-small lung cancer: a southwest oncology group pilot study. Cancer Treat Rep 65: 143–144PubMedGoogle Scholar
  49. Mattson K, Holsti LR, Salmo M, Saastamoinen M, Ahlstedt S, Holsti P (1980) Vindesine in the treatment of small cell and non-small cell bronchogenic carcinoma: preliminary results. Cancer Treat Rev (Suppl) 7: 65–70CrossRefGoogle Scholar
  50. Miller T, McMahon U, Livingston RB (1980) Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi). Cancer Treat Rep 64: 1241–1245PubMedGoogle Scholar
  51. Milstein D, Robinson E (1981) Four-drug combination chemotherapy in advanced lung cancer: methotrexate, doxorubicin, cyclophosphamide and CCNU. Cancer 48: 2358–2363PubMedCrossRefGoogle Scholar
  52. Minna J, Higgins GA, Glatstein EL (1982) Cancer of the lung. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds). Cancer-principles and practice of oncology. Lippincott, Philadelphia Toronto pp 396–474Google Scholar
  53. Mitrou PS, Fischer M, Schneider M (1981) Chemotherapy of inoperable non-Small cell carcinoma of the lung with vindesine, cis-platinum and cyclophosphamide: a pilot study. In: Brade W, Nagel GA, Seeber S (eds) Proceedings of the International Vinca Alkaloid-Symposium Vindesine, Frankfurt/Main 1980. Karger, Basel München Paris London New York Sydney, pp 405–409Google Scholar
  54. Monfardini S, Brunner K, Crowther D, Olive D, MacDonald J, Eckhardt S, Whitehouse J (1981) Manual of cancer chemotherapy, 3rd edn. UICC, Geneva, pp 123–127 (with the collaboration of Reed D)Google Scholar
  55. Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW (1981) Ifosfamide: A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65: 693–695PubMedGoogle Scholar
  56. Nichols WC, Eagan RT, Frytak S, Ingle JN, Creagan ET, Kvols LK (1980) Phase II evaluation of AMSA in patients with metastatic lung cancer. Cancer Treat Rep 64: 1383–1385PubMedGoogle Scholar
  57. Osterlind K, Horbov S, Dombernowsky P, Rorth M, Hansen HH (1982) Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung. Cancer Treat Rep 66: 305–309PubMedGoogle Scholar
  58. Pannuti F, Lelli G, Casadio M, Piana E, DiMarco AR (1980) High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: A randomized trial. Cancer Treat Rep 64: 1131–1134PubMedGoogle Scholar
  59. Pisoni MB, Libretti A, Piazza E et al. (1981) Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma. Cancer Treat Rep 65: 731–732PubMedGoogle Scholar
  60. Richards F, Howard V, Shore A et al. (1981) Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: A prospective randomized study for the Piedmont Oncology Association. Cancer 47: 2827–2832PubMedCrossRefGoogle Scholar
  61. Rosenthal CJ, Ritter S, Platica O (1982) Bleomycin, cisplatin, vincristine, and methotrexate in advanced non-small cell bronchogenic carcinoma. Cancer Treat Rep 66: 205–206PubMedGoogle Scholar
  62. Rozenczweig M, Kenis Y (1975) European studies with adriamycin in lung cancer. Cancer Treat Rep (3) 6: 343–347Google Scholar
  63. Ruckdeschel JC, Codish SB, Stranaham A, McKneally MF (1972) Postoperative empy-ema improves survival in lung cancer. Demonstration and analysis of a natural experiment. N Engl J Med 287: 1013PubMedCrossRefGoogle Scholar
  64. Ruckdeschel YC, Mehta CR, Salazar OM, Cohen M, Vogel S, Koons LS, Lerner H (1981a) Chemotherapy for inoperable non-small cell bronchogenic carcinoma: EST 2575, Generation II. Cancer Treat Rep 65: 965–972Google Scholar
  65. Ruckdeschel KC, Mehta CR, Salazar OM, Creech RH, Sponzo RW (1981b) Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, Generation III, HAM versus CAMP. Cancer Treat Rep 65: 959–963Google Scholar
  66. Samson MK, Freile RJ, Baker LH, Cummings G, Talley RW (1981) Phase II study of AMSA in lung cancer. Cancer Treat Rep 65: 655–658PubMedGoogle Scholar
  67. Schaerer R, Sotto JJ, Wiget U, Perdix A, Beusa JC, Ribaud P (1977) Chemotherapy of bronchogenic carcinomas by a combination of cyclophosphamide, methotrexate, vincristine and bleomycin. Eur J Cancer Clin Oncol 13: 425–428Google Scholar
  68. Schulman P, Budman DR, Vinciguerra V, Weiselberg L, Abrams S, Degnan T (1982) Phase II study of divided-dose vinblastine in non-small cell bronchogenic carcinoma. Cancer Treat Rep 66: 171–172PubMedGoogle Scholar
  69. Serrou B, Cupissol D, Favier F, Michel FB (1981) Opposite results in two randomized trials evaluating the adjunct value of peripheral intravenous nutrition in lung cancer patients. 3rd International Conference on the adjuvant Therapy of Cancer, March 18–21, 1981, Tucson, Arizona, USA (Abstr Vol 30 )Google Scholar
  70. Stoopler MB, Kelsen DP, Gralla RJ, Casper ES, Cheng E, Golbey RB (1980) Vindesine, cis-dichlorodiammineplatinum (II), cytoxan and adriamycin combination chemotherapy in non-small cell lung cancer. Proc Am Assoc Cancer Res 21: 457Google Scholar
  71. Takita H, Marabella PC, Edgerton F, Rizzo D (1979) Cis-dichlorodiammineplatinum (II), adriamycin, cÿclophosphamide, CCNU, and vincristine in non-small cell lung carcinoma: a preliminary report. Cancer Treat Rep 63: 29–33PubMedGoogle Scholar
  72. Takita H, Hollinshead AC, Bjornsson B (1980) Chemotherapy, surgery and immunotherapy of inoperable lung cancer. Proc Am Assoc Cancer Res 19:C-50Google Scholar
  73. Valaitis J, Warren S, Gamble D (1981) Increasing incidence of adenocarcinoma of the lung. Cancer 47: 1042–1046PubMedCrossRefGoogle Scholar
  74. Vincent RG, Lane WW, Raza S, Madajewicz S (1982) Cisplatin combination chemotherapy in non-oat cell carcinoma of the lung. Cancer Treat Rep 66: 197–198PubMedGoogle Scholar
  75. Vogelzang NJ, Bonomi PD, Rossof AH, Wolter J (1978) Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CMAP) treatment of non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62: 1595–1597PubMedGoogle Scholar
  76. Vogl SE, Wollner D, Kaplan BH, Berenzweig M (1980) Combination chemotherapy for non-small cell bronchogenic carcinoma with bleomycin, doxorubicin, methotrexate, and dis-dichlorodiammineplatinum (II) (BAMP). Cancer Treat Rep 64: 717–719PubMedGoogle Scholar
  77. Wheeler RH, Liepman MK, Baker SR, Earhart RH, Bull FE, Ensminger WD (1980) Bleomycin, vincristine, and mitomycin C with or withouthmethotrexate in the treatment of squamous cell carcinoma. Cancer Treat Rep 64: 943–949PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • H. O. Klein

There are no affiliations available

Personalised recommendations